Status:
TERMINATED
Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy
Lead Sponsor:
Abbott Nutrition
Conditions:
Cow's Milk Allergy
Eligibility:
All Genders
3-12 years
Phase:
NA
Brief Summary
This is a multi-center, randomized, double-blind, placebo-controlled food challenge to be conducted in infants or children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day ope...
Eligibility Criteria
Inclusion
- Participant has a physician diagnosis of IgE-mediated Cow's Milk Allergy (CMA) based on a clinical history of a reaction resulting in characteristic immediate hypersensitivity symptoms within 2 hours of oral exposure or immediate hypersensitivity symptoms according to physician's observation
- Participant is willing to undergo confirmatory testing or must have had at least one of the following within 6 months of enrollment:
- Documentation of milk-specific serum IgE \>15 kIUA/L or \> 5 kIUA/L if younger than 1 year.
- Documented cow's milk skin prick test mean wheal \>10mm
- Physician-supervised oral food challenge that elicited immediate, objective, allergic symptoms.
- Participant agrees to stop oral steroid use within 14 days and antihistamine use within 7 days of confirmation of diagnosis and food challenges.
- Participant had followed a strict cow's milk protein-free diet prior to enrollment.
- Parent(s) confirm their intention not to administer any products containing cow's milk protein during the study.
- Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.
Exclusion
- Participant is exclusively breastfed at the time of enrollment.
- Participant is consuming an amino acid-based formula due to failure on an extensively hydrolyzed formula.
- Significant chronic medical diseases including major chromosomal or congenital anomalies, gastrointestinal diseases or abnormalities other than CMA, immunodeficiencies, unstable asthma, asthma treated with biologics (omalizumab or other monoclonal antibody), FPIES, eosinophilic esophagitis, and severe uncontrolled eczema.
- Previous severe anaphylactic reaction to cow's milk within the last two years.
- An adverse medical history or current condition that is thought by the investigator to have potential for effects on tolerance or the hypoallergenicity test.
- Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent.
- Participant is routinely consuming baked milk products.
Key Trial Info
Start Date :
January 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 18 2022
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04910373
Start Date
January 25 2022
End Date
February 18 2022
Last Update
July 5 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
2
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30329
3
UNC-Chapel Hill
Chapel Hill, North Carolina, United States, 27599
4
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104